Moreover, our newly developed method could be utilized to assess the effects of clinical PARPi on subnuclear PARP1 localization in cancer-relevant model systems, such as BRCA-deficient cells or cell lines with other homologous recombination deficiencies. Here, PARP1 is linked to cancer.